Markets

U.S. open in 1 hrs, 3 mins
10,023.42
17.46
 
0.17%
2,112.44
7.12
 
0.34%
1,069.30
2.67
 
0.25%
101.031
0.00
 
0.00%
5,211.66
68.94
 
1.34%
9,808.99
19.64
 
0.20%
22,207.55
377.83
 
1.73%
0.0128
 
0.86%
0.06
 
0.07%
1,107.60
12.50
 
1.14%
78.54
1.11
 
1.43%
Bookmark and Share

Wide World of Stocks to Air on FOX Affiliates In New York and Los Angeles

Business Wire
posted: 123 DAYS 20 HOURS AGO
Text SizeAAA
The producers of a new program featuring microcap stocks, called Wide World of Stocks, have purchased air time on FOX affiliates in New York and Los Angeles. A 30-minute taped episode about biotech firm Viral Genetics (Pink Sheets: VRAL), will broadcast on WLNY, New York, on July 12 at 11:30 a.m. and 2:00 a.m. Eastern time. The same show, which features the company’s CEO Haig Keledjian discussing Viral Genetics’ drug therapies for HIV/AIDs, Lyme Disease and cancer, will air on Los Angeles’ KTTV on July 12 at 2:00 a.m. Pacific time.
The broadcast schedule is being updated as Wide World of Stocks producers purchase additional air time. It’s available at www.wideworldofstocks.com, where visitors also can register to receive alerts of additional broadcasts. Episodes of Wide World of Stocks will be available for viewing at the site, after they have broadcast on network or cable television.
The episode featuring Viral Genetics will be accessible to more than 100 million households through paid programming during July. During interviews with the show’s host Damon Roberts and co-hosts Roland Rick Perry and Thomas McCarthy, "The Dean" of CollegeStock.com, Mr. Keledjian focused on the company’s international human clinical trials of a drug compound that reduced the viral load and symptoms of HIV/AIDs. He also discussed two recent additions to the company’s advisory board. Dr. Luc Montagnier won a Nobel Prize in 2008 for his role in discovering HIV. Dr. Leslie Z. Benet is an internationally recognized drug development expert. Details are available at www.viralgenetics.com.
About Viral Genetics, Inc.:
Viral Genetics, Inc. is engaged in the discovery and development of immune-based therapies for HIV/AIDS and other autoimmune diseases using its thymus nuclear protein compound (TNP). Viral Genetics believes that its investigational HIV/AIDS drug based on TNP, called VGV-1, represents a unique approach to treating HIV/AIDS that focuses on boosting the immune system to allow the body to fight HIV more efficiently. See: www.viralgenetics.com. None of the information contained on this website is incorporated by reference herein.
Not a Broker/Dealer or Financial Advisor:
We are not a Registered Broker/Dealer or Financial Advisor, nor do we hold ourselves out to be a Registered Broker/Dealer or Financial Advisor. All materials presented in this press release, television show and on our website are not to be regarded as investment advice and are only for informative purposes. Readers should verify all claims and do their own due diligence before investing in featured companies. Investing in small-cap, micro cap and penny stock securities is speculative and carries a high degree of risk.
No Offer of Securities :
None of the information featured in this press release constitutes an offer or solicitation to purchase or to sell any securities of Viral Genetics, Inc.
Current Ownership of Shares:
Affiliates of Wild World of Stocks, Inc. currently own securities of Viral Genetics, Inc. This is an inherent conflict of interest.
Compensation:
An Affiliate of Wide World of Stocks, Inc. has agreed to provide consulting services to Viral Genetics, Inc. in exchange for up to 19 million shares of common stock and 12 million warrants of Viral Genetics, Inc. upon the completion of certain milestones. This is an inherent conflict of interest. As of the date of this press release, no shares of common stock or warrants have been issued pursuant to this agreement.
SAFE HARBOR FOR FORWARD-LOOKING STATEMENTS:
Information presented in this press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Exchange Act of 1933 and Section 21B of the Securities Exchange Act of 1934. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact may be "forward-looking statements". Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward-looking statements in this action may be identified through use of words such as "projects", "foresee", "expects", "will", "anticipates", "estimates", "believes", "understands", or that by statements indicating certain actions "may", "could", or "might" occur. Understand there is no guarantee past performance will be indicative of future results.
None of the information contained on our website, www.WideWorldofStocks.com, is incorporated by reference herein.
Copyright Business Wire 2009
2009-07-08 12:44:00
COMMENTS ( 0 )
GOT SOMETHING TO SAY?
YOU'LL BE ASKED TO REGISTER OR SIGN IN BEFORE POSTING A COMMENT.
Make a Comment
Comment
 
Download the Daily Finance iPhone Application

Headlines From AOL Money & Finance Partners

CNBC
The Big Money
Smart Money
Kiplinger.com
    The street

    Visit Money & Finance for stock quotes, the web's best online portfolio manager and the latest business & financial news. Find out about every aspect of personal finance and money management, from finding the best mortgage rates and preventing identity theft to making money, saving money and investing money.